Clinical Trial Detail

NCT ID NCT02368951
Title Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Bayer

Advanced Solid Tumor


Aprutumab ixadotin

Age Groups: adult

Additional content available in CKB BOOST